Neonc Technologies Holdings, Inc. key statistics and ratios
In fiscal 2025, Neonc Technologies Holdings, Inc. had an operating margin of -145637.5% and a current ratio of 0.07. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2024Dec 2024 | 2025Dec 2025 |
|---|---|---|
| Operating margin | <−999% | <−999% |
| Net margin | <−999% | <−999% |
| Free-cash-flow margin | — | <−999% |
| Return on assets | −348.2% | <−999% |
| Asset turnover | 0.02 | 0.01 |
| Current ratio | 0.25 | 0.07 |
| Interest cover (operating income ÷ interest) | n/m | n/m |
| R&D as % of revenue | >999% | >999% |
| Capital spending as % of revenue | — | >999% |
| Quarter | 2024 Q2Jun 2024 | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | <−999% | — | <−999% | <−999% | — | — | — | — |
| Net margin | <−999% | — | <−999% | <−999% | — | — | — | — |
| Current ratio | — | — | 0.25 | 0.41 | 0.11 | 0.19 | 0.07 | 0.18 |
| R&D as % of revenue | >999% | — | >999% | >999% | — | — | — | — |
| SG&A as % of revenue | — | — | — | 337.3% | — | — | — | — |
Financial health
- Short-term assets cover short-term liabilities $4m of assets due within a year against $24m of liabilities due within a year.
- Short-term assets cover long-term liabilities $4m short-term assets against $254,548 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$42m against $3m of interest.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Compare with peers
- Lyell Immunopharma, Inc. statistics
- AIM Immunotech Inc. statistics
- Ibio, Inc. statistics
- Lisata Therapeutics, Inc. statistics
- Celldex Therapeutics, Inc. statistics
Head to head: LYEL vs NTHIAIM vs NTHIIBIO vs NTHI
More: Biotechnology stocks compared, Health Care sector, rankings of US companies